Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,556.37
(
0.00%
)
US TECH 100
23,561.60
(
0.87%
)
Dow Jones
46,124.06
(
0.00%
)
Brent Oil
96.20
(
-0.32%
)
Bitcoin
71,424.00
(
1.28%
)
News Focus
News Focus
Post# of 257275
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122807
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 241868

Thursday, 04/14/2022 10:00:19 AM

Thursday, April 14, 2022 10:00:19 AM

Post# of 257275
MRK’s V116—(follow-on_to Vaxneuvance)—receives FDA BTD for prevention of pneumococcal disease in adults:

https://finance.yahoo.com/news/merck-announces-u-fda-granted-104500278.html

The phase-3 trial is expected to start during 2022.

V116 is a 21-valent vaccine; the 21 strains are: 3, 6A/C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B/C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, 35B.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today